Sonodynamic therapy augmented by glycolysis inhibition: a novel metabolic reprogramming strategy for enhanced osteosarcoma treatment.

ABSTRACT: A metabolic reprogramming strategy, considered an efficient way to enhance current therapies, has provided renewed hope for treating osteosarcoma (OS), which has reached a bottleneck in clinical practice. In this study, SHK@Mn-TiO₂ were developed as novel sonodynamic therapy (SDT) agents with glycolysis-inhibiting properties. By reducing the expression of pyruvate kinase isozyme M2 (PKM2) and hexokinase-2 (HK-2), SHK@Mn-TiO₂ effectively inhibited glycolysis, thereby reversing the hypoxic tumor microenvironment (TME), as evidenced by a more than ∼50% decrease in hypoxia-inducible factor-1α (HIF-1α) and lactate (LA) levels compared with those of Mn-TiO₂. Under this O₂-enriched TME, SHK@Mn-TiO₂ enhanced intracellular reactive oxygen speci

SUBMITTER: Song Z 

PROVIDER: S-EPMC12573261 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature